HEADWAY-DLB is a global Phase 2b multi-center, double-blind, placebo-controlled clinical study evaluating intepirdine (RVT-101) in patients with dementia with Lewy bodies (DLB).
The efficacy, safety, and tolerability of intepirdine at doses of 70 mg and 35 mg daily will be evaluated over a 24-week treatment period in approximately 240 patients with DLB. Patients currently receiving stable background therapy for DLB will be allowed to participate in the study. The primary efficacy evaluations are the Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC+) and a computerized cognitive battery. Patients who complete the HEADWAY-DLB study will be eligible to receive intepirdine in an extension study. If you are interested in learning more information please email HEADWAYDLB@Axovant.com
or call +1 (646) 677-5778